EMA Authorised: Abecma (idecabtagene vicleucel) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Abecma (idecabtagene vicleucel) for treatment of multiple myeloma in adults. It is designated as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Abecma (idecabtagene vicleucel)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 13/11/2025. Orphan medicine